AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20017910
Drug: Atorvastatin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin monotherapy (10 mg)
Trial: 17005079
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no additional GTD treatment)
Trial: 15357626
Drug: Heberon Alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heberon Alfa R (formulation A)
Trial: 15357626
Drug: Viraferon (formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viraferon (formulation B)
Trial: 11132386
Drug: Artemether-lumefantrine (median
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-lumefantrine (median total dose of 9.6 mg/kg and 57.9 mg/kg of lumefantrine)
Trial: 11132386
Drug: Artesunate-mefloquine (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate-mefloquine (12 mg/kg over 3 days and 25 mg/kg)
Trial: 27329582
Drug: rivaroxaban (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rivaroxaban (10 mg/d for 14 days beginning 2-3 hours post-operation)
Trial: 27329582
Drug: aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aspirin (100 mg/d for 3 months beginning 2-3 hours post-operation)
Trial: 20212251
Drug: Cladribine at
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cladribine at 0.12 mg/kg combined with cyclophosphamide at 250 mg/m2 for 3 days intravenously (CC regimen)
Trial: 20212251
Drug: Fludarabine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine at 25 mg/m2 combined with cyclophosphamide at 250 mg/m2 for 3 days intravenously (FC regimen)
Trial: 3794876
Drug: Three weekly
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three weekly (tiw) injections of hGH (0.24 IU hGH/kg body weight/wk)
Trial: 3794876
Drug: Two weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two weekly (biw) injections of hGH (0.24 IU hGH/kg body weight/wk)
Trial: 11728078
Drug: Flurbiprofen (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen (n 12, 2 x 100 mg)
Trial: 11728078
Drug: Tiaprofenic acid
RxNorm normalized name: tiaprofenic acid
DrugBank: Tiaprofenic acid (DB01600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiaprofenic acid (n 14, 2 x 300 mg)
Trial: 31345626
Drug: Chemoradiotherapy (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiotherapy (two cycles of cisplatin 50 mg/m2 during radiotherapy, followed by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m2)
Trial: 25026672
Drug: Weekly Application
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly Application of Pesticide (WAP)
Trial: 20093894
Drug: Omega-3 supplement
RxNorm normalized name: Systane Vitamin Omega-3 Supplement Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 supplement (1,200 mg eicosapentaenoic acid and 800 mg docosahexaenoic acid)
Trial: 16127078
Drug: Doripenem 500
RxNorm normalized name: doripenem 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doripenem 500 mg administered over 1 h every 8 h
Trial: 16127078
Drug: Prolonged infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged infusions of doripenem
Trial: 7608317
Drug: Roferon-A reconstituted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roferon-A reconstituted with 10 mg of HSA
Trial: 1978736
Drug: Fenoldopam (FD)
DrugBank: Fenoldopam (DB00800)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fenoldopam (FD) at doses from 0.05 to 0.50 micrograms/kg/min
Trial: 328540
Drug: Spironolactone and
RxNorm normalized name: Spironolactone and torsemide only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone and hydrochlorothiazide combination therapy
Trial: 29243273
Drug: Continuous Positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Positive Airway Pressure (CPAP) therapy for nonsleepy OSA patients (n = 122)
Trial: 29243273
Drug: Continuous Positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Positive Airway Pressure (CPAP) therapy for sleepy OSA patients (n = 155)
Trial: 21898717
Drug: Augmentation strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentation strategy
Trial: 15186737
Drug: Interferon-alpha 2b,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alpha 2b, cyclophosphamide, and prednisone as maintenance therapy
Trial: 15186737
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no maintenance therapy)
Trial: 11297816
Drug: Ketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.5 mg/kg over 60 min)
Trial: 9043726
Drug: Lorazepam (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (0.03 mg.kg‐1 sl), morphine (0.15 mg.kg‐1 im), and perphenazine (0.05 mg.kg‐1 im)
Trial: 9043726
Drug: Lorazepam (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (0.03 mg.kg‐1 sl) and saline (1.5 ml im)
Trial: 7709624
Drug: Single procedure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single procedure of manual therapy
Trial: 28207529
Drug: Dexmedetomidine without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine without loading dose (PRDo)
Trial: 28207529
Drug: Propofol/remifentanil/Ringer solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol/remifentanil/Ringer solution (PRR)
Trial: 28207529
Drug: Dexmedetomidine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine with loading dose (PRDw)
Trial: 17315426
Drug: Patient-controlled epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled epidural analgesia with pethidine (25 mg of five mg/ml solution, lockout of 10 minutes, maximum dose of 150 mg/four hours)
Trial: 17315426
Drug: Nurse-administered epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-administered epidural pethidine (bolus of 50 mg, maximum dose of 50 mg/two hours)
Trial: 14626183
Drug: Astragalus injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astragalus injection (AI) combined with chemotherapy
Trial: 8962554
Drug: Medication alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication alone (simvastatin)
Trial: 3842611
Drug: All contrast
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All contrast agents
Trial: 27791254
Drug: AGV with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGV with adjunctive triamcinolone (TA group)
Trial: 24686255
Drug: Fasinumab 0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasinumab 0.03 mg/kg
Trial: 19443679
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg and Ezetimibe 10 mg
Trial: 17877648
Drug: Inhaled human
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled human insulin (Exubera; EXU)
Trial: 15077226
Drug: Amifostine (740
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amifostine (740 mg/m2 for 2 doses preceding BCNU)
Trial: 12453890
Drug: 0.3 mU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mU · kg1 · min‐1 insulin infusion
Trial: 2246576
Drug: Rifampicin locally
RxNorm normalized name: rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifampicin locally (ointment)
Trial: 6446852
Drug: Immediate Treatment
RxNorm normalized name: Aquaphor Immediate Relief Lip Balm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate Treatment Group (Acupuncture)
Trial: 6446852
Drug: Delayed Treatment
RxNorm normalized name: GRANULES, DELAYED RELEASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed Treatment Group (Acupuncture after initial control)
Trial: 6446852
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (Immediate and Delayed Treatment)
Trial: 6446852
Drug: Inadequate Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inadequate Treatment Group (Control)
Trial: 22684355
Drug: Budesonide 400
RxNorm normalized name: Budesonide 400 microgram/actuation powder for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 400 mcg twice daily
Trial: 20332245
Drug: GH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH therapy for 4 months (36 microg/kg x d)
Trial: 20332245
Drug: Delayed start
RxNorm normalized name: Star Anise Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed start of GH therapy (untreated for 4 months, then GH for 4 months)
Trial: 18564796
Drug: Ephedrine (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine (initial dose 50 mg infused over 30 minutes, dose intervals of 5 mg)
Trial: 18564796
Drug: Mephentermine (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mephentermine (initial dose 50 mg infused over 30 minutes, dose intervals of 5 mg)
Trial: 15373702
Drug: H. pylori
RxNorm normalized name: H. PYLORI AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori eradication (treated with omeprazole and antibiotics)
Trial: 8195678
Drug: Prinomide (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prinomide (1500 mg/day)
Trial: 8195678
Drug: Naproxen (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (1500 mg/day)
Trial: 2977043
Drug: Oral dose
RxNorm normalized name: Exactamed Oral Dose Syringe 35cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose of 3 X 100 mg MPA
Trial: 2977043
Drug: Weekly changing
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly changing scheme with 2 X 10 mg Tamoxifen and 3 X 100 mg MPA
Trial: 2977043
Drug: Oral dose
RxNorm normalized name: Exactamed Oral Dose Syringe 35cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose of 1000 mg MPA daily (in 4 patients with ovarian carcinoma)
Trial: 28986606
Drug: Breviscapine (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breviscapine (120 mg daily, 40 mg three times a day for 14 days)
Trial: 17010994
Drug: Olanzapine treatment
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine treatment (10-20mg/day)
Trial: 16234007
Drug: Alvimopan 12
RxNorm normalized name: alvimopan 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alvimopan 12 mg twice daily with placebo
Trial: 16234007
Drug: Alvimopan 12
RxNorm normalized name: alvimopan 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alvimopan 12 mg twice daily with codeine 30 mg 4 times/day
Trial: 16234007
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with codeine 30 mg 4 times/day
Trial: 12483729
Drug: IDEC‐131 (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDEC‐131 (2.5 mg/kg to 10.0 mg/kg)
Trial: 9690596
Drug: Spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia (2 mL 0.5% dibucaine)
Trial: 9690596
Drug: Epidural anesthesia
RxNorm normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural anesthesia (20 mL 2% mepivacaine)
Trial: 2686547
Drug: norfloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: norfloxacin (400 mg three times a day)
Trial: 2686547
Drug: pefloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pefloxacin (400 mg three times a day)
Trial: 27564925
Drug: Laser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser therapy (λ of 640 nm and SAEF of 1.06 J/cm2)
Trial: 27564925
Drug: LED therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LED therapy (λ of 660 ± 20 nm and SAEF of 0.24 J/cm2)
Trial: 18842959
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group with personally relevant statement
Trial: 17257479
Drug: Oral linezolid
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral linezolid during hospitalization and after discharge
Trial: 17257479
Drug: IV vancomycin/oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV vancomycin/oral linezolid switch
Trial: 10442373
Drug: Uracil/tegafur (UFT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uracil/tegafur (UFT) 250 mg/m2/day plus oral calcium folinate 45 mg/day
Trial: 24698346
Drug: Beta-carotene (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene (30 mg/d)
Trial: 2213107
Drug: 13-cis retinoic
RxNorm normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 13-cis retinoic acid (1 mg/kg/d)
Trial: 21350025
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human IL-6 (rhIL-6) infusion into the peritendinous tissue of the Achilles tendon
Trial: 19106357
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate (MTX) injected intravascularly at 100 mg/m² plus 200 mg/m² in 500 mL of normal saline solution with folinic acid rescue
Trial: 17179377
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (n = 22)
Trial: 11230464
Drug: 5 cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 cycles of 4'-epidoxorubicin 60 mg/m² days 1 and 2 and ifosfamide 1.8 g/m² days 1 through 5, with hydration, mesna, and granulocyte colony-stimulating factor
Trial: 1291521
Drug: 40% citric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40% citric acid treatment to remove smear layer with Tubliseal
Trial: 1291521
Drug: 40% citric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40% citric acid treatment to remove smear layer with Vitrebond
Trial: 1679324
Drug: Rational Emotive
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rational Emotive Therapy (RET)
Trial: 17429726
Drug: Oral pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pantoprazole (80 mg BID for 3 days)
Trial: 17429726
Drug: Intravenous pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous pantoprazole (80 mg IV bolus and 8 mg/hr infusion for 3 days)
Trial: 14767029
Drug: FTY (0.25-3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTY (0.25-3.5 mg)
Trial: 14767029
Drug: FTY (0.25-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTY (0.25-2 mg)
Trial: 14767029
Drug: FTY (0.25-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTY (0.25-2 mg) or (3.5 mg)
Trial: 14767029
Drug: FTY (high-dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTY (high-dose)
Trial: 11436678
Drug: Isosorbide 5-mononitrate
RxNorm normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide 5-mononitrate (Mononit) 10 or 20 mg twice a day
Trial: 2575572
Drug: Somatostatin administration
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin administration for two days
Trial: 2575572
Drug: No somatostatin
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No somatostatin administration (Control)
Trial: 28591778
Drug: 2D_M0,6 (2-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2D_M0,6 (2-dose schedule at months 0 and 6)
Trial: 28591778
Drug: 2D_M0,12 (2-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2D_M0,12 (2-dose schedule at months 0 and 12)
Trial: 28591778
Drug: 3D_M0,1,6 (3-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3D_M0,1,6 (3-dose schedule at months 0, 1, and 6)
Trial: 26114996
Drug: Telemedicine intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telemedicine intervention with diabetes educators videoconferencing monthly to review glucose and blood pressure readings.
Trial: 26114996
Drug: Changing medication
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Changing medication dose (as opposed to starting or stopping a medication).
Trial: 26114996
Drug: Adjusting glucose-lowering
RxNorm normalized name: biguanide blood glucose lower drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusting glucose-lowering agents compared with antihypertensive or antilipid medications.
Trial: 22890639
Drug: Clazosentan (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clazosentan (5 mg/h)
Trial: 16818012
Drug: Cisplatin-based combination
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based combination neoadjuvant chemotherapy
Trial: 16818012
Drug: Local therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local therapy alone
Trial: 16818012
Drug: Immediate cystectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate cystectomy with adjuvant chemotherapy
Trial: 16818012
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with monitoring of response
Trial: 12697594
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine 0.05 mg
Trial: 2843255
Drug: Low-dose heparin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose heparin + dihydroergotamine (A)
Trial: 2843255
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin + dihydroergotamine (B)
Trial: 31420748
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg IR on awakening QD
Trial: 31420748
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg DR following breakfast QM
Trial: 31420748
Drug: 37.5 mg
RxNorm normalized name: pemoline 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 37.5 mg DR following breakfast QM
Trial: 31420748
Drug: DR groups
RxNorm normalized name: Dr. Numb
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DR groups (25 mg and 37.5 mg)
Trial: 31201692
Drug: Intraperitoneal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal bupivacaine (20 ml of 2.5% bupivacaine hydrochloride)
Trial: 31201692
Drug: Control (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0 ml of bupivacaine)
Trial: 19672175
Drug: Ephedrine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine (8 mg/ml)
Trial: 19672175
Drug: Phenylephrine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine (100 microg/ml)
Trial: 16139450
Drug: Estrogen/hormone therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen/hormone therapy (ET/HT) for 3 years
Trial: 16139450
Drug: Estrogen/hormone therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen/hormone therapy (ET/HT)
Trial: 9311511
Drug: Formoterol inhaled
RxNorm normalized name: formoterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol inhaled at high flow rate (120 L.min-1)
Trial: 9311511
Drug: Formoterol inhaled
RxNorm normalized name: formoterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol inhaled at low flow rate (60 L.min-1)
Trial: 8318319
Drug: fentanyl 5
RxNorm normalized name: fentanyl 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fentanyl 5 micrograms ml‐1
Trial: 8318319
Drug: combined group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combined group (0.125% bupivacaine with fentanyl 5 micrograms ml‐1)
Trial: 31693541
Drug: GET Living
RxNorm normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GET Living (graded exposure treatment)
Trial: 22573599
Drug: Cognitive Stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Stimulation Therapy (CST) for 7 weeks
Trial: 21981842
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with rosuvastatin 20 mg and fenofibric acid 135 mg
Trial: 21981842
Drug: Rosuvastatin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin monotherapy (10, 20, or 40 mg)
Trial: 21981842
Drug: Rosuvastatin 5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 5, 10, 20, or 40 mg; fenofibric acid 135 mg
Trial: 14666012
Drug: 200 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/kg Salvia miltiorrhiza intravenously after anesthesia induction and at the time of rewarming (n=10)
Trial: 10705191
Drug: Fiuggi mineral
RxNorm normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fiuggi mineral water (oligomineral water with a calcium content of 15 mg/l)